Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Single and Repeated Dose Escalation Study of GSK2838232
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT02795754
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 10
- Registration Number
- NCT02770378
- Locations
- 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 472
- Registration Number
- NCT02652624
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 578
- Registration Number
- NCT02603107
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02565888
- Locations
- 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands
Titrating-Dose of Lonafarnib in Combination With Ritonavir
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eiger BioPharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02527707
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2018-09-25
- Target Recruit Count
- 22
- Registration Number
- NCT02511431
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 7
- Registration Number
- NCT02503462
- Locations
- 🇨🇭
Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland
Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Viriom
- Target Recruit Count
- 24
- Registration Number
- NCT02489487
- Locations
- 🇹🇭
Faculty of Medicine, Siriraj Hospital, Bangkok, Wanglang Road, Thailand
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 150
- Registration Number
- NCT02470650
- Locations
- 🇪🇸
Josep Mallolas Masferrer, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.